scholarly journals Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

2013 ◽  
Vol 39 (1) ◽  
pp. 27-43 ◽  
Author(s):  
John M. Kirkwood ◽  
Ahmad Tarhini ◽  
Joseph A. Sparano ◽  
Prapti Patel ◽  
Joan H. Schiller ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Solid Tumors ◽  
Systemic Adjuvant Therapy ◽  
Clinical Benefits

The Pattern of Metastases in Human Breast Cancer Influence of systemic adjuvant therapy and impact on survival

1988 ◽  
Vol 27 (6) ◽  
pp. 715-719 ◽  
Author(s):  
C. Kamby ◽  
B. Ejlertsen ◽  
J. Andersen ◽  
N. E. Birkler ◽  
L. Rytter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Impact On Survival ◽  
Systemic Adjuvant Therapy

Devising Two-Stage and Multistage Phase II Studies on Systemic Adjuvant Therapy for Uveal Melanoma

2012 ◽  
Vol 53 (8) ◽  
pp. 4986 ◽  
Author(s):  
John Whitehead ◽  
Svetlana Tishkovskaya ◽  
Jemma O'Connor ◽  
Bertil Damato
Keyword(s):  
Adjuvant Therapy ◽  
Uveal Melanoma ◽  
Phase Ii ◽  
Two Stage ◽  
Phase Ii Studies ◽  
Systemic Adjuvant Therapy

Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer

1999 ◽  
Vol 17 (5) ◽  
pp. 1458-1458 ◽  
Author(s):  
Nicole Hébert-Croteau ◽  
Jacques Brisson ◽  
Jean Latreille ◽  
Gilles Gariépy ◽  
Caty Blanchette ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Adjuvant Treatment ◽  
Minimal Risk ◽  
Node Negative ◽  
Risk Of Recurrence ◽  
Consensus Recommendations ◽  
Node Negative Breast Cancer ◽  
Systemic Adjuvant Therapy

PURPOSE: We conducted a population-based study in Quebec, Canada, to assess longitudinal changes in systemic adjuvant therapy for node-negative breast cancer. MATERIALS AND METHODS: A stratified random sample was selected among women with newly diagnosed node-negative breast cancer in 1988, 1991, and 1993. Information on the patient, her tumor, source of care, and treatment was abstracted from medical charts. Patients were classified as being at minimal, moderate, or high risk of recurrence on the basis of criteria proposed at the 4th International Conference on Adjuvant Therapy of Primary Breast Cancer (St. Gallen, Switzerland, 1992), and systemic adjuvant treatment received was dichotomized as being consistent or not consistent with consensus recommendations. RESULTS: Overall, 1,578 cases of invasive breast carcinoma were reviewed. The proportion of patients who were given hormonal or cytotoxic treatment increased from 51.7% to 73.1% from 1988 to 1993. Virtually all women at minimal risk were treated in 1991 and 1993 according to the consensus statement. The proportions of women so treated were 75.0% and 65.4% in the moderate- and high-risk categories, respectively, in 1991. In 1993, these proportions were 71.4% and 67.0%, respectively. Omission of chemotherapy, especially in high-risk women with estrogen receptor–negative tumors who were 50 to 69 years of age, was the most frequent inconsistency with guidelines. CONCLUSION: Systemic adjuvant therapy for node-negative breast cancer has gained acceptance. Better understanding of the decision-making process, of the perception of the risks and benefits involved, and of the impact of alternative strategies for the dissemination of consensus recommendations are needed to promote the use of chemotherapy in specific categories of women who are at high risk of recurrence.

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.

1998 ◽  
Vol 16 (4) ◽  
pp. 1380-1387 ◽  
Author(s):  
C Lindley ◽  
S Vasa ◽  
W T Sawyer ◽  
E P Winer
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Adjuvant Therapy ◽  
Sexual Function ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Systemic Adjuvant Therapy

PURPOSE To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS Eighty-six patients who had completed systemic adjuvant therapy for early-stage breast cancer between 1988 and 1991 were surveyed by written questionnaire and telephone interview. Sociodemographic information was obtained for each patient, and patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), the Medical Outcomes Study (MOS) Short Form 36 (SF-36), a series of questions regarding sexual function, and a survey about preferences for adjuvant therapy in relation to possible benefit. RESULTS The mean FLIC score among all patients was 138.3 (+/- 12.2), which suggests a high level of QOL. The reported frequency of moderate to severe symptoms was generally low (ie, < 15%), with fatigue (31.4%), insomnia (23.3%), and local numbness at the site of surgery (22.1%) occurring with greatest frequency. Patients reported a wide range of sexual difficulties. Preference assessment showed that more than 65% of patients were willing to undergo 6 months of chemotherapy for a 5% increase in likelihood of cancer cure. CONCLUSION Self-rated QOL in breast cancer patients 2 to 5 years following adjuvant therapy was generally favorable. Less than one third of patients reported moderate to severe symptoms. Selected aspects of sexual function appeared to be compromised. The majority of patients indicated a willingness to accept 6 months of chemotherapy for small to modest potential benefit.

0-54. Local irradiation reduces breast relapses in the presence of systemic adjuvant therapy

The Breast ◽  
1997 ◽  
Vol 6 (4) ◽  
pp. 240
Author(s):  
I. Potyka ◽  
M. Fennessy ◽  
D.L. Riley ◽  
J. Houghton ◽  
M. Baum
Keyword(s):  
Adjuvant Therapy ◽  
Local Irradiation ◽  
Systemic Adjuvant Therapy

Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed

2019 ◽  
pp. e126-e140 ◽  
Author(s):  
Kimberly Levinson ◽  
Oliver Dorigo ◽  
Krista Rubin ◽  
Kathleen Moore
Keyword(s):  
Solid Tumors ◽  
Solid Tumor ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Gynecologic Cancer ◽  
Hematologic Malignancies ◽  
Next Generation ◽  
Gynecologic Cancers ◽  
Clinical Benefits

Immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs), has been transformative in both solid tumor and hematologic malignancies. Patients with previously terminal illnesses have experienced profound responses of great durability with these agents, fueling excitement among patients and providers regarding their use. Unfortunately, the gains seen in some solid tumors have not been replicated in a large percentage of patients with gynecologic cancer. This review focuses on the clinical benefits seen to date, toxicities and management when using ICIs, ways to improve prediction of who should receive immunotherapy, and a discussion of next-generation immunotherapy with cellular therapeutics and how these might relate to gynecologic cancers.

Sign in / Sign up

Export Citation Format

Share Document